Fig. 5

F-AgNPs mediated antigen modification cooperates with CAR-T cell therapy in vivo. a Schematic illustration of treatment process in subcutaneous tumor model. b, c Enhanced antitumor effect of F-AgNPs mediated antigen modification cooperative with CAR-T cell therapy in a subcutaneous MKN45 tumor model. Tumor growth profiles (b) and survival curve (c) of mice treated with PBS, F-AgNPs, EvIII CAR-T, F-AgNPs + EvIII CAR-T respectively. Tumor volume were analyzed with one-way ANOVA. Data are represented as mean ± s.e.m. n = 6. Survival curves were analyzed with log-rank test. n = 6. *p < 0.05; **p < 0.01; ***p < 0.001. d Schematic illustration of treatment process in peritoneal metastasis tumor model. e–g Enhanced antitumor effect of F-AgNPs mediated antigen modification cooperative with CAR-T cell therapy in a disseminated peritoneal MGC803 tumor model. Tumor growth profiles (e, f) and survival curve (g) of mice treated with PBS, F-AgNPs, EvIII CAR-T, F-AgNP s + EvIII CAR-T respectively. Data are represented as mean ± s.e.m.., n = 6. A one-way ANOVA was used for statistical analysis. *p < 0.05; **p < 0.01; ***p < 0.001